Abiraterone needs to be taken for about two months to have effect, some patients can see the effect in less than 1 month, the specific time of effect there are individual differences. Abiraterone is a CYP17 inhibitor, clinically mainly used in combination with prednisone to treat patients with metastatic refractory prostate cancer who have received prior chemotherapy containing polyene paclitaxel. It can also be used to treat newly diagnosed high-risk metastatic endocrine therapy-sensitive prostate cancer. The drug is usually taken for about two months before it is effective, the exact time of effect varies from person to person, and some patients can see the effect in less than one month of use. Prostate-specific antigen (PSA) can be monitored regularly during use, and if the PSA decreases the treatment is effective. Adverse reactions such as hypertension, hypokalemia, and fluid retention may occur during use. If the adverse reactions are severe, the medication needs to be stopped and treated in a hospital. The medication should be used under medical supervision.